136 related articles for article (PubMed ID: 36100144)
1. Clinical characteristics and treatment of IMP-type carbapenemase-producing Enterobacteriaceae bacteremia: Case series and literature review.
Soneda K; Uda K; Araki K; Murakoshi T; Yuza Y; Saito O; Kinoshita K; Higuchi H; Horikoshi Y
J Infect Chemother; 2023 Jan; 29(1):26-32. PubMed ID: 36100144
[TBL] [Abstract][Full Text] [Related]
2. IMP-6 Carbapenemase-Producing Enterobacteriaceae Bacteremia Successfully Treated with Amikacin-Meropenem in Two Patients.
Nakakura I; Ogawa Y; Sakakura K; Imanishi K; Hirota K; Shimatani Y; Uehira T; Nakamori S; Sako R; Doi T; Yamazaki K
Pharmacotherapy; 2017 Oct; 37(10):e96-e102. PubMed ID: 28699652
[TBL] [Abstract][Full Text] [Related]
3. Comparison between IMP carbapenemase-producing Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: a multicentre prospective study of the clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae.
Hayakawa K; Nakano R; Hase R; Shimatani M; Kato H; Hasumi J; Doi A; Sekiya N; Nei T; Okinaka K; Kasahara K; Kurai H; Nagashima M; Miyoshi-Akiyama T; Kakuta R; Yano H; Ohmagari N
J Antimicrob Chemother; 2020 Mar; 75(3):697-708. PubMed ID: 31789374
[TBL] [Abstract][Full Text] [Related]
4. Epidemiological, clinical, and microbiological characteristics of carbapenemase-producing Enterobacteriaceae bloodstream infection in the Republic of Korea.
Park JW; Lee H; Park SY; Kim TH
Antimicrob Resist Infect Control; 2019; 8():48. PubMed ID: 30873279
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Microbiological Characteristics of Bacteremia Caused by Carbapenemase-producing Enterobacterales in Minami Ibaraki Area, Japan.
Uchida M; Terada N; Saito K; Ishikawa H; Funayama Y; Oishi T; Shinohara H; Ebihara T; Kurihara Y; Hitomi S
J Microorg Control; 2024; 29(2):81-89. PubMed ID: 38880620
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant
Wang X; Wang Q; Cao B; Sun S; Zhang Y; Gu B; Li B; Liao K; Zhao F; Jin L; Jin C; Yang C; Pei F; Zhang Z; Wang H
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348660
[TBL] [Abstract][Full Text] [Related]
7. Trends and molecular characteristics of carbapenemase-producing Enterobacteriaceae in Japanese hospital from 2006 to 2015.
Eda R; Nakamura M; Takayama Y; Maehana S; Nakano R; Yano H; Kitasato H
J Infect Chemother; 2020 Jul; 26(7):667-671. PubMed ID: 32222331
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular analyses of bloodstream infections caused by IMP metallo-β-lactamase-producing Enterobacteriaceae in a tertiary hospital in Japan.
Mori N; Kagawa N; Aoki K; Ishi Y; Tateda K; Aoki Y
J Infect Chemother; 2020 Jan; 26(1):144-147. PubMed ID: 31427199
[TBL] [Abstract][Full Text] [Related]
9. Development of selective medium for IMP-type carbapenemase-producing Enterobacteriaceae in stool specimens.
Yamamoto N; Kawahara R; Akeda Y; Shanmugakani RK; Yoshida H; Hagiya H; Hara N; Nishi I; Yukawa S; Asada R; Sasaki Y; Maeda K; Sakamoto N; Hamada S; Tomono K
BMC Infect Dis; 2017 Mar; 17(1):229. PubMed ID: 28340557
[TBL] [Abstract][Full Text] [Related]
10. In vitro effect of an antimicrobial combination therapy without colistin and tigecycline for CPE and non-CPE.
Okanda T; Matsumoto T
J Infect Chemother; 2020 Apr; 26(4):322-330. PubMed ID: 31924522
[TBL] [Abstract][Full Text] [Related]
11. Rapid detection method of carbapenemase-producing Enterobacteriaceae by MALDI-TOF MS with imipenem/cilastatin (KB) disc and zinc sulfate solution.
Oho M; Funashima Y; Nagasawa Z; Miyamoto H; Sueoka E
J Infect Chemother; 2021 Feb; 27(2):205-210. PubMed ID: 33008738
[TBL] [Abstract][Full Text] [Related]
12. Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae.
Marimuthu K; Ng OT; Cherng BPZ; Fong RKC; Pada SK; De PP; Ooi ST; Smitasin N; Thoon KC; Krishnan PU; Ang MLT; Chan DSG; Kwa ALH; Deepak RN; Chan YK; Chan YFZ; Huan X; Zaw Linn K; Tee NWS; Tan TY; Koh TH; Lin RTP; Hsu LY; Sengupta S; Paterson DL; Perencevich E; Harbarth S; Teo J; Venkatachalam I;
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383670
[TBL] [Abstract][Full Text] [Related]
13. Bloodstream infections caused by IMP-8-producing Enterobacteriaceae isolates: the need for clinical laboratory detection of metallo-β-lactamases?
Yan JJ; Lee NY; Chen HM; Wang MC; Ko WC; Tsai LH; Wu JJ
Eur J Clin Microbiol Infect Dis; 2013 Mar; 32(3):345-52. PubMed ID: 23001510
[TBL] [Abstract][Full Text] [Related]
14. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.
García-Castillo M; García-Fernández S; Gómez-Gil R; Pitart C; Oviaño M; Gracia-Ahufinger I; Díaz-Regañón J; Tato M; Cantón R;
Int J Antimicrob Agents; 2018 Mar; 51(3):511-515. PubMed ID: 29371104
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-control-control study.
Nicolas-Chanoine MH; Vigan M; Laouénan C; Robert J;
Eur J Clin Microbiol Infect Dis; 2019 Feb; 38(2):383-393. PubMed ID: 30488368
[TBL] [Abstract][Full Text] [Related]
16. Genotypic Distribution and Antimicrobial Susceptibilities of Carbapenemase-Producing
Jeong S; Lee N; Park MJ; Jeon K; Kim HS; Kim HS; Kim JS; Song W
Ann Lab Med; 2022 Jan; 42(1):36-46. PubMed ID: 34374347
[TBL] [Abstract][Full Text] [Related]
17. Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries.
Villegas MV; Pallares CJ; Escandón-Vargas K; Hernández-Gómez C; Correa A; Álvarez C; Rosso F; Matta L; Luna C; Zurita J; Mejía-Villatoro C; Rodríguez-Noriega E; Seas C; Cortesía M; Guzmán-Suárez A; Guzmán-Blanco M
PLoS One; 2016; 11(4):e0154092. PubMed ID: 27104910
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal Genomic Characterization of Carbapenemase-producing Enterobacteriaceae (CPE) Reveals Changing Pattern of CPE Isolated in Hong Kong Hospitals.
Zhu C; Li C; Lai CKC; Ng R; Chau KY; Wong KT; Lo NWS; Barua N; Yang Y; Liyanapathirana V; Hui M; Lai RW; Fung KSC; Tsang DN; Ip M
Int J Antimicrob Agents; 2021 Nov; 58(5):106430. PubMed ID: 34525401
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-UK).
Woodford N; Xu-McCrae L; Mushtaq S; Wu HHT; Ellington MJ; Lancaster O; Davies F; Donaldson H; Rao GG; Verma A; Wareham DW; Ciesielczuk H; Stone GG; Irani PM; Bracher S; Hawkey PM
J Antimicrob Chemother; 2018 Mar; 73(3):698-702. PubMed ID: 29253163
[TBL] [Abstract][Full Text] [Related]
20. A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant
Saito S; Hayakawa K; Tsuzuki S; Ishikane M; Nagashima M; Mezaki K; Sugiki Y; Tajima T; Matsunaga N; Ide S; Kinoshita N; Kusama Y; Fujitomo Y; Nakamoto T; Toda Y; Kaku M; Kodama EN; Ohmagari N
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33257451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
